On October 31, 2023, Indaptus Therapeutics, Inc. released, in abstract form, interim data from the first cohort of four patients in its Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data demonstrated that, as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20. First cohort patients received a single dose of 7x10 killed Decoy20 bacteria via a one-hour IV infusion.

As of August 31, 20 23, treatment-related adverse events, potentially expected based upon prior clinical studies with purified lipopolysaccharide, have included, among other events, changes in hemodynamic parameters, transaminase elevations, and lymphopenia; all resolved with or without treatment within 30 minutes to 3 days. The Company will be presenting the interim data in full at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 4, 2023.